Spots Global Cancer Trial Database for zd6474
Every month we try and update this database with for zd6474 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC | NCT00410189 | Lung Cancer | ZD6474 | 18 Years - | M.D. Anderson Cancer Center | |
| Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD) | NCT00862836 | Ovarian Cancer | Vandetanib | 18 Years - | Sanofi | |
| This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | NCT00059722 | Carcinoma, Non-... | ZD6474 Placebo ZD1839 | 18 Years - | Sanofi | |
| ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | NCT00071188 | Carcinoma, Non-... | ZD6474 Paclitaxel Carboplatin | 18 Years - | Sanofi | |
| Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer | NCT00613626 | Small Cell Lung... | Cisplatin Etoposide Placebo ZD6474 | 18 Years - | Hoosier Cancer Research Network | |
| This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. | NCT00047840 | Non-Small Cell ... | ZD6474 Placebo Docetaxel | 18 Years - | Sanofi | |
| Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer | NCT00098345 | Thyroid Cancer | ZD6474 (vandeta... | 18 Years - 130 Years | Sanofi | |
| Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors | NCT00551096 | Malignant Solid... Biliary Cancer Pancreatic Canc... | Gemcitabine Capecitabine ZD6474 | 18 Years - | University of Colorado, Denver | |
| Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck | NCT00459043 | Squamous Cell C... | ZD6474 Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer | NCT00034918 | Breast Neoplasm... Metastases, Neo... | ZD6474 | 18 Years - | Sanofi | |
| Phase II Study of ZD6474 in Advanced NSCLC | NCT00290537 | Lung Cancer | ZD6474 Carboplatin Paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases | NCT00807170 | Non-small Cell ... | ZD6474 (Vandeta... Whole Brain Rad... ZD6474 ZD6474 | 18 Years - | Sanofi | |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | NCT00613054 | Glioblastoma Gliosarcoma | Zactima, Gleeve... | 18 Years - | Duke University | |
| Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma | NCT00681798 | Pancreatic Canc... | Vandetanib | 18 Years - | Sanofi | |
| Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck | NCT00459043 | Squamous Cell C... | ZD6474 Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC | NCT00410189 | Lung Cancer | ZD6474 | 18 Years - | M.D. Anderson Cancer Center | |
| Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors | NCT00441142 | Glioblastoma Mu... Gliosarcoma | ZD6474 temozolomide Radiation Thera... | 18 Years - | Dana-Farber Cancer Institute | |
| Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases | NCT00807170 | Non-small Cell ... | ZD6474 (Vandeta... Whole Brain Rad... ZD6474 ZD6474 | 18 Years - | Sanofi | |
| This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | NCT00059722 | Carcinoma, Non-... | ZD6474 Placebo ZD1839 | 18 Years - | Sanofi | |
| ZD6474 to Treat Advanced Brain Cancer in Patients | NCT00272350 | Recurrent High-... Progressive Low... Malignant Gliom... | Steroids ZD6474 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer | NCT00496509 | Colorectal Canc... | ZD6474 (Zactima... Dynamic Contras... Biomarker Draws ZD6474 (Zactima... | 18 Years - | Sanofi | |
| This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. | NCT00047840 | Non-Small Cell ... | ZD6474 Placebo Docetaxel | 18 Years - | Sanofi | |
| Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC) | NCT00745732 | Non-Small Cell ... | ZD6474 (ZACTIMA... Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer | NCT00047788 | Multiple Myelom... | ZD6474 VEGF-receptor t... | 18 Years - | Sanofi | |
| Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | NCT00507091 | Metastatic Colorectal Adenocarcinoma | ZD6474 (vandeta... Irinotecan 5-Fluorouracil Leucovorin ZD6474 (vandeta... | 18 Years - | Sanofi | |
| Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | NCT00613223 | Gliosarcoma Glioblastoma | Vandetanib and ... | 18 Years - | Duke University | |
| ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer | NCT00436072 | Colorectal Canc... | ZD6474 Cetuximab Irinotecan | 18 Years - | Dana-Farber Cancer Institute | |
| ZD6474 to Treat Advanced Brain Cancer in Patients | NCT00272350 | Recurrent High-... Progressive Low... Malignant Gliom... | Steroids ZD6474 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | NCT00613054 | Glioblastoma Gliosarcoma | Zactima, Gleeve... | 18 Years - | Duke University | |
| This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | NCT00059722 | Carcinoma, Non-... | ZD6474 Placebo ZD1839 | 18 Years - | Sanofi | |
| This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. | NCT00047840 | Non-Small Cell ... | ZD6474 Placebo Docetaxel | 18 Years - | Sanofi | |
| An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | NCT00410761 | Thyroid Cancer | ZD6474 (Vandeta... | 18 Years - | Sanofi | |
| BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC | NCT00410189 | Lung Cancer | ZD6474 | 18 Years - | M.D. Anderson Cancer Center | |
| ZD6474 to Treat Advanced Brain Cancer in Patients | NCT00272350 | Recurrent High-... Progressive Low... Malignant Gliom... | Steroids ZD6474 | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
